News for Karuna Therapeutics, Inc. (KRTX)

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to tr

EMA committee recommends repotrectinib for lung cancer

The S&P 500 added 0.1% on Monday, Nov. 11, 2024, closing above the 6,000-point milestone as investors continued to weigh the implications of the election.

Bristol-Myers Squibb stock hits 52-week high of $60.65

Bristol Myers Squibb SVP Phil Holzer sells $38,930 in stock

Earnings call: Bristol-Myers Squibb reports robust Q3 growth, raises guidance

PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults

Advancements and Projections in the Pharmaceutical Intermediates Market: Insights, Trends, Opportunities, and Recent Developments...

PureTech Health plc (NASDAQ:NASDAQ:PRTC) Q2 2024 Earnings Conference Call August 28, 2024 9:00 AM ETCompany ParticipantsAllison Mead Talbot - Head of...

The markets had a strong week, with the S&P 500 gaining 0.97%. Click here to read more about the portfolio's addition and the game plan for the week ahead.

Cerevel Therapeutics presents a potential arbitrage opportunity with its acquisition by AbbVie, offering over 10% returns for investors. Read more on CERE stock.

PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share

Insight into the Fund's Latest Investment Decisions and Stock Adjustments Vanguard Health Care Fund (Trades, Portfolio), managed by Wellington Management Compan

Bristol-Myers Squibb Company (NYSE: BMY) reported an adjusted loss per share of $4.40, narrower than the Zacks Consensus Estimate of a loss of $4.53 per share. In the year-ago quarter, BMY posted adjusted earnings per share of $2.05.

Bristol Myers Squibb's market capitalization has declined significantly due to the impending expiration of patents for its flagship drugs. Learn more on BMY stock here.

Biotech M&A activity surged at the end of 2023, which helped small biotech sector surge. Find out 3 logical buyout targets in biotech/biopharma space in 2024.

Karuna Therapeutics, Inc. dropped from S&P Biotechnology Select Industry Index...

In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.